Cambridge Antibody Tech Group PLC
8 March 2002
02/CAT/ 10
Not for release or publication in or into Japan, Australia or the Republic of
Ireland
FOR IMMEDIATE RELEASE
23.00 GMT 18.00 EST Friday 8 March 2002
For Further Information Contact: Weber Shandwick Square Mile (Europe)
Cambridge Antibody Technology Tel: +44 (0) 20 7950 2800
Tel: +44 (0) 1763 263 233 Kevin Smith
John Aston, Finance Director Graham Herring
Rowena Gardner, Head of Corporate
Communications
BMC Communications/The Trout Group (USA)
Tel: 001 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext.15 (investors)
Cambridge Antibody Technology announces the share Exchange Ratio for its
Offer to Acquire all of the Outstanding Common Shares of Drug Royalty
Corporation and that it will pay the Top Up Amount and the Additional
Top Up Amount entirely in Cambridge Antibody Technology Shares
Melbourn, UK and Toronto, Canada... In connection with the outstanding offer to
acquire all of the common shares of Drug Royalty Corporation Inc. (TSE:DRI) by
Cambridge Antibody Technology Group plc ("CAT") (LSE: CAT; NASDAQ: CATG) through
its wholly-owned subsidiary 3982904 Canada Inc. (the "Offeror"), the Offeror
hereby announces the determination this afternoon of the CAT Share Exchange
Ratio as required by the terms of the Offer. The Offeror further announces that
it will pay the Top Up Amount and the Additional Top Up Amount entirely in CAT
Shares (or CAT ADSs, if the CAT ADS Option is chosen) and that the Maximum Share
Condition in the Offer has therefore been fulfilled.
The CAT Share Exchange Ratio was determined to be 0.095. Taking into account the
Top Up Amount and the Additional Top Up Amount, DRC Shareholders will therefore
be entitled to receive 0.095 CAT Shares (or CAT ADSs, if the CAT ADS Option is
chosen) for each DRC Share tendered to the Offer. Based on today's closing CAT
Share price on the London Stock Exchange and on today's pound sterling/Canadian
dollar noon exchange rate, as reported by the Bank of Canada, the Offer is equal
to C$3.10 per DRC Share. The Offer remains open for acceptance by DRC
Shareholders until 9:00 p.m. (EST) on Tuesday March 12, 2002.
CAT and the Offeror have elected not to deliver to DRC an amended Offer in
response to DRC's proposed agreement with Inwest Investment Ltd.
The CAT Share Exchange Ratio, Top Up Amount and Additional Top Up Amounts were
calculated in accordance with the terms of the Offer contained in the take-over
bid circular dated February 1, 2002 (the "Circular"). The terms "Additional Top
Up Amount", "CAT ADS", "CAT ADS Option", "CAT Share", "CAT Share Exchange
Ratio", "DRC Share", "Maximum Share Condition", "Offer" and "Top Up Amount" used
in this press release shall have the meaning ascribed thereto in the Circular.
This announcement is being made pursuant to section 1 of the Offer.
-ENDS-
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.